Lixte Biotechnology Holdings Inc (LIXT) - Total Liabilities

Latest as of March 2026: $1.69 Million USD

Based on the latest financial reports, Lixte Biotechnology Holdings Inc (LIXT) has total liabilities worth $1.69 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Lixte Biotechnology Holdings Inc to evaluate the company's liquid asset resilience ratio.

Lixte Biotechnology Holdings Inc - Total Liabilities Trend (2005–2025)

This chart illustrates how Lixte Biotechnology Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LIXT total asset value.

Lixte Biotechnology Holdings Inc Competitors by Total Liabilities

The table below lists competitors of Lixte Biotechnology Holdings Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Menderes Tekstil Sanayi ve Ticaret AS IS:MNDRS	Turkey	TL7.21 Billion
Hancom WITH Inc KQ:054920	Korea	₩94.68 Billion
Ascot Resources Ltd. TO:AOT	Canada	CA$417.06 Million
South West Pinnacle Exploration Limited NSE:SOUTHWEST	India	Rs1.29 Billion
Kingstate Electronics TWO:3206	Taiwan	NT$1.54 Billion
Hyperfine Inc NASDAQ:HYPR	USA	$14.26 Million
DarioHealth Corp NASDAQ:DRIO	USA	$41.50 Million
artnet AG Namens-Aktien o.N. XETRA:ART	Germany	€29.69 Million

Liability Composition Analysis (2005–2025)

This chart breaks down Lixte Biotechnology Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Lixte Biotechnology Holdings Inc balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.78	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.21	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.16	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Lixte Biotechnology Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Lixte Biotechnology Holdings Inc (2005–2025)

The table below shows the annual total liabilities of Lixte Biotechnology Holdings Inc from 2005 to 2025.

Year	Total Liabilities	Change
2025-12-31	$1.77 Million	+456.76%
2024-12-31	$318.28K	+1.41%
2023-12-31	$313.86K	-20.50%
2022-12-31	$394.79K	+30.32%
2021-12-31	$302.93K	+39.90%
2020-12-31	$216.52K	-8.98%
2019-12-31	$237.90K	+12.79%
2018-12-31	$210.91K	-43.46%
2017-12-31	$373.02K	+70.60%
2016-12-31	$218.65K	-23.45%
2015-12-31	$285.64K	+4.46%
2014-12-31	$273.44K	-15.02%
2013-12-31	$321.77K	+23.21%
2012-12-31	$261.15K	-25.54%
2011-12-31	$350.75K	+79.81%
2010-12-31	$195.06K	-35.04%
2009-12-31	$300.26K	-19.97%
2008-12-31	$375.20K	+48.78%
2007-12-31	$252.18K	+102.55%
2006-12-31	$124.50K	+896.02%
2005-12-31	$12.50K	--

About Lixte Biotechnology Holdings Inc

NASDAQ:LIXT USA Electrical Equipment & Parts

Market Cap

$64.50 Million

Market Cap Rank

#21008 Global

#4744 in USA

Share Price

$3.71

Change (1 day)

-9.51%

52-Week Range

$2.44 - $8.04

All Time High

$81.00